Search
for
Sort by
Research 361–390 of 846
- Antitumor Activities of the Typhonium flagelliforme Extract Combined with Natural Interferons of Canine and Feline in Mice with DMBA Induced Skin Tumors
- Patched-assoziierte Tumoren: Modifikatorgene und Pathogenese
- Clinical aspects of the metabolic syndrome
- Steroid Hormones of Reproduction and Sexual Development
- Unravelling the link between insulin resistance and androgen excess
- Tinea Capitis Kerion Type: A Case Report
- An Analysis of the Correlation between Alopecia and Chief Complaints
- Epimorphic regeneration in mice is p53-independent
- El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
- Role of phosphatidylinositol 3‐kinase signaling pathway in radiation‐induced liver injury
- Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial
- Sorafenib stimulates human skin type mast cell degranulation and maturation
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Inhibition of T-cell activity in alopecia areata: recent developments and new directions
- Cell type‐specific actions of thyroid hormones in nonalcoholic steatohepatitis and liver fibrosis
- Anticancer activity of cepharanthine on non-small cell lung cancer cells
- Adrenal myelolipoma: A rare entity
- A Cost-per-Responder Analysis of Ritlecitinib vs Baricitinib in Severe Alopecia Areata
- Using patient preference to inform ritlecitinib dose selection for alopecia areata treatment
- Current best evidence in pigmentary dermatology
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Alopecia, ascites, and incomplete regeneration after 85 to 90 per cent liver resection
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
- Sequential Morphologic and Clinicopathologic Alterations in Dogs with Experimentally Induced Glucocorticoid Hepatopathy
- Cutaneous toxicity as a predictive biomarker for clinical outcome in patients receiving anticancer therapy
- Elevated <em>DKK1</em> expression is an independent unfavorable prognostic indicator of survival in head and neck squamous cell carcinoma
- Regulatory T‐cells in alopecia areata
- Angiogenin is expressed in human dermal papilla cells and stimulates hair growth
- [Cutaneous manifestations of zinc deficiency in ethylic cirrhosis].